Oct 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
Oct 01, 2019
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
Sep 03, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
Aug 07, 2019
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
Aug 01, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
Jul 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
Jun 18, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
Jun 17, 2019
Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference
May 29, 2019
Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer
May 14, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study
May 08, 2019
Protagonist Therapeutics Reports First Quarter 2019 Financial Results
May 08, 2019
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
May 07, 2019
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019
Apr 01, 2019
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
Mar 12, 2019
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Mar 05, 2019
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results
Feb 21, 2019
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
Jan 16, 2019
Protagonist Therapeutics Reports Granting of Inducement Award
Jan 09, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
Jan 07, 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology